Literature DB >> 920764

Effects of antenatal exposure to anorectic drugs.

L Milkovich, B J van der Berg.   

Abstract

In a large prospective, observational study of pregnancy and child development, the anorectic drugs (amphetamines and phenmetrazine) prescribed to gravid women during different stages of pregnancy were evaluated for their teratogenicity. The severe congenital anomaly rate (SCA) per 100 live-born children at age five years did not differ from the SCA rate of the group of children whose mothers did not use these drugs. There was, however, an excess of oral clefts in the offspring of mothers who had amphetamines prescribed in the first 56 days from the last menstrual period. A rought test of efficacy of anorectic drugs by comparing mean weight gains in four-week periods before and after the prescription showed only short-term and limited reduction of weight gain.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 920764     DOI: 10.1016/0002-9378(77)90645-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  11 in total

1.  Teratogenic Effects of `Recreational' Drugs: Increasing the risk of congenital anomalies.

Authors:  J E Polifka; J M Friedman
Journal:  Can Fam Physician       Date:  1991-09       Impact factor: 3.275

2.  ADHD Medication Use During Pregnancy and Risk for Selected Birth Defects: National Birth Defects Prevention Study, 1998-2011.

Authors:  Kayla N Anderson; Annelise C Dutton; Cheryl S Broussard; Sherry L Farr; Jennifer N Lind; Susanna N Visser; Elizabeth C Ailes; Stuart K Shapira; Jennita Reefhuis; Sarah C Tinker
Journal:  J Atten Disord       Date:  2018-03-09       Impact factor: 3.256

3.  Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium.

Authors:  Krista F Huybrechts; Gabriella Bröms; Lotte Brix Christensen; Kristjana Einarsdóttir; Anders Engeland; Kari Furu; Mika Gissler; Sonia Hernandez-Diaz; Pär Karlsson; Øystein Karlstad; Helle Kieler; Anna-Maria Lahesmaa-Korpinen; Helen Mogun; Mette Nørgaard; Johan Reutfors; Henrik Toft Sørensen; Helga Zoega; Brian T Bateman
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

Review 4.  ADHD treatment and pregnancy.

Authors:  Frank M C Besag
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

Review 5.  Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women.

Authors:  Marcela C Smid; Torri D Metz; Adam J Gordon
Journal:  Clin Obstet Gynecol       Date:  2019-03       Impact factor: 2.190

Review 6.  Exposure to attention deficit hyperactivity disorder medications during pregnancy.

Authors:  Caitlin Humphreys; Facundo Garcia-Bournissen; Shinya Ito; Gideon Koren
Journal:  Can Fam Physician       Date:  2007-07       Impact factor: 3.275

7.  Amphetamine secretion in breast milk.

Authors:  E Steiner; T Villén; M Hallberg; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 8.  Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation.

Authors:  Asher Ornoy
Journal:  Pharm Res       Date:  2018-02-06       Impact factor: 4.200

Review 9.  The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review.

Authors:  Asher Ornoy; Gideon Koren
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 10.  Maternal Use of Weight Loss Products and the Risk of Neural Tube Defects in Offspring: A Systematic Literature Review.

Authors:  Thanh T Hoang; A J Agopian; Laura E Mitchell
Journal:  Birth Defects Res       Date:  2017-10-12       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.